Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2000 3
2001 1
2002 2
2003 2
2004 2
2007 1
2008 1
2009 1
2010 1
2011 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.
Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. Meditz AL, et al. J Infect Dis. 2011 Feb 15;203(4):442-51. doi: 10.1093/infdis/jiq085. Epub 2011 Jan 18. J Infect Dis. 2011. PMID: 21245157 Free PMC article.
Safety profile of recombinant canarypox HIV vaccines.
de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC. de Bruyn G, et al. Vaccine. 2004 Jan 26;22(5-6):704-13. doi: 10.1016/j.vaccine.2003.08.023. Vaccine. 2004. PMID: 14741163 Clinical Trial.
Vpr is preferentially targeted by CTL during HIV-1 infection.
Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, Khatri A, Strick D, Phillips MN, Cohen GB, Islam SA, Kalams SA, Brander C, Goulder PJ, Rosenberg ES, Walker BD; HIV Study Collaboration. Altfeld M, et al. J Immunol. 2001 Sep 1;167(5):2743-52. doi: 10.4049/jimmunol.167.5.2743. J Immunol. 2001. PMID: 11509618 Free article.
17 results